Merck's Winrevair Shows Positive Results in Phase 3 Trial, Reducing Risk of Death

Nov 25, 2024, 12:00 PM

Merck announced on Monday that its drug, Winrevair (sotatercept-csrk), has shown significant results in reducing the risk of death in patients with a rare lung condition that causes high blood pressure. The announcement follows the Pivotal Phase 3 ZENITH Trial, which met its primary endpoint at an interim analysis. This development comes months after the drug secured approval in the United States.